<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cystic fibrosis: Management of advanced lung disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cystic fibrosis: Management of advanced lung disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cystic fibrosis: Management of advanced lung disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Simon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Chmiel, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2581318340">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cystic fibrosis (CF) is a multisystem disorder caused by pathogenic mutations of the
         <em>
          CFTR
         </em>
         gene (CF transmembrane conductance regulator). Pulmonary disease remains the leading cause of morbidity and mortality in patients with CF. When CF lung disease becomes severe, additional evaluation and treatment are overlaid onto the standard therapies that are applicable to all patients with CF lung disease. This expanded management approach has been published as a consensus guideline by the CF Foundation [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Management of advanced lung disease in CF is discussed below. Other aspects of CF-associated lung disease are discussed in the following topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The diagnosis and pathophysiology of CF and its manifestations in other organ systems are also discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14544.html" rel="external">
          "Cystic fibrosis-related diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">
          "Cystic fibrosis: Overview of gastrointestinal disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">
          "Cystic fibrosis: Assessment and management of pancreatic insufficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">
          "Cystic fibrosis: Hepatobiliary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1446502639">
         <span class="h1">
          DEFINITION OF ADVANCED CYSTIC FIBROSIS LUNG DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is appropriate to use a relatively broad definition to avoid excluding any patient who might benefit from the treatments that are recommended for severely affected patients. Based on a systematic review of the literature, the CF Foundation guidelines committee defined advanced CF lung disease as [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) &lt;40% predicted when stable,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Referred for lung transplantation evaluation,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One or more of the following clinical characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Previous intensive care unit (ICU) admission for respiratory failure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercarbia (arterial partial pressure of carbon dioxide [PaCO
         <sub>
          2
         </sub>
         ] &gt;50 mmHg or tension of carbon dioxide in peripheral venous blood [PvCO
         <sub>
          2
         </sub>
         ] &gt;56 mmHg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Daytime resting oxygen requirement
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary hypertension (on echocardiogram)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe functional impairment from respiratory disease (New York Heart Association class IV)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Six-minute walk test distance &lt;400 m
        </p>
        <p>
        </p>
        <p>
         In addition, it was recognized that some patients who do not meet the above definition have clinical characteristics that predict accelerated deterioration and who might benefit from early application of the expanded treatments. These conditions include frequent pulmonary exacerbations, rapid rate of FEV
         <sub>
          1
         </sub>
         decline, supplemental oxygen for exercise or sleep, worsening malnutrition, infection with difficult-to-manage organisms, CF-related diabetes, pneumothorax, and massive hemoptysis requiring ICU or bronchial artery embolization. Children with moderately severe lung disease should also be considered for early implementation because their rate of deterioration must have been relatively rapid for them to have reached severe lung disease at a young age.
        </p>
        <p class="headingAnchor" id="H2883888830">
         <span class="h1">
          ADVANCED CARE DIRECTIVES
         </span>
         <span class="headingEndMark">
          —
         </span>
         When patients progress to having advanced lung disease, discussions should be held regarding prognosis and care options. Family members and friends should be included, if requested by the patient. The clinician should guide the discussion to include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detailed information about lung transplantation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         End-of-life options, with recording of the patient's preferences in a living will, depending on state or local laws
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decisions about who will serve as the patient's health care proxy/durable power of attorney
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2597121385">
         <span class="h1">
          CHRONIC INTERVENTIONS TO SUPPORT HEALTH
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a patient's lung disease progresses, the CF clinician should review the treatment program to ensure that all standard evaluations and therapies are being implemented. For patients with advanced lung disease, the following areas should be given special attention:
        </p>
        <p class="headingAnchor" id="H1771886249">
         <span class="h2">
          Key therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CF transmembrane conductance regulator (CFTR) modulators
         </strong>
         – Therapy with a CFTR modulator therapy is appropriate for most patients with advanced lung disease. Selection of therapy depends on the patient's genotype  (
         <a class="graphic graphic_algorithm graphicRef130532" href="/z/d/graphic/130532.html" rel="external">
          algorithm 1
         </a>
         ). Although patients with advanced lung disease were poorly represented in the early clinical trials of CFTR modulators [
         <a href="#rid2">
          2
         </a>
         ], accumulating evidence supports the use of modulators in these patients. In a prospective study in 245 patients with severe lung disease, treatment with
         <a class="drug drug_pediatric" data-topicid="122969" href="/z/d/drug information/122969.html" rel="external">
          elexacaftor-tezacaftor-ivacaftor
         </a>
         for three months was associated with significant improvements in percent predicted forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) and body weight and decreased need for supplemental oxygen or referral for lung transplantation [
         <a href="#rid3">
          3
         </a>
         ]. Additional information regarding CFTR modulator therapy in patients with advanced lung disease is available in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators", section on 'Patients with advanced lung disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators", section on 'Pulmonary outcomes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data regarding the use of CFTR modulators after lung transplantation are limited to small retrospective case series [
         <a href="#rid4">
          4
         </a>
         ]. The decision to prescribe them will need to balance the extrapulmonary benefits with side effects, drug-drug interactions, and cost [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators", section on 'Post-transplant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary rehabilitation
         </strong>
         – All patients with CF who have limited functional activity due to pulmonary disease should have a prescribed pulmonary exercise/rehabilitation program. This is particularly important for those with advanced lung disease whose activities of daily living are becoming impaired and in preparation for lung transplantation. (See
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutritional status
         </strong>
         – As lung disease progresses, many patients with CF develop nutritional failure. Because of the tight link between pulmonary and nutritional status, treating advanced lung disease requires attention to nutrition. Enteral tube feeding is recommended when oral intake is insufficient to achieve adequate weight. The CF Foundation's enteral feeding guidelines state that low FEV
         <sub>
          1
         </sub>
         is not an absolute contraindication for percutaneous insertion of a feeding tube, but the risk of tube insertion needs to be considered [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sinonasal disease
         </strong>
         – Virtually all patients with advanced CF lung disease have chronic sinusitis. A retrospective study of patients with advanced CF lung disease reported that sinonasal symptom scores improved markedly following initiation of
         <a class="drug drug_pediatric" data-topicid="122969" href="/z/d/drug information/122969.html" rel="external">
          elexacaftor-tezacaftor-ivacaftor
         </a>
         [
         <a href="#rid7">
          7
         </a>
         ]. Although endoscopic sinus surgery improves symptoms in those who are refractory to medical therapy, surgery does not appear to alter the pattern of pulmonary function decline and is not recommended except for symptom control [
         <a href="#rid8">
          8-10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Sinus and nasopharyngeal disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CF-related diabetes
         </strong>
         – Patients should be rigorously screened for CF-related diabetes, which is common in CF and is associated with worse lung function, poorer nutritional status, and more chest infections. For patients with CF-related diabetes, insulin therapy has beneficial effects on nutrition and probably improves pulmonary function and survival. (See
         <a class="medical medical_review" href="/z/d/html/14544.html" rel="external">
          "Cystic fibrosis-related diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled antibiotics
         </strong>
         – For patients with chronic
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         infection and advanced lung disease, many experts recommend continuous alternating inhaled antibiotics. This practice is based primarily on clinical experience and observational evidence. A randomized clinical trial to evaluate the benefits of this approach failed to enroll the targeted number of patients due in part to the widespread adoption of continuous altering antibiotics in clinical practice for patients with frequent pulmonary exacerbations [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2157262154">
         <span class="h2">
          Psychosocial support
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adherence
         </strong>
         – Standard pulmonary treatments prescribed for CF patients are complex and time-consuming. The problem is compounded in patients with advanced lung disease who have difficulties performing their activities of daily living. Consistently obtaining medications and equipment is made more difficult by shifting insurance coverage and prior approval rules, changes in preferred formularies, and the need to use multiple pharmacies [
         <a href="#rid12">
          12
         </a>
         ]. Special efforts need to be made to assist patients in navigating these challenges. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Chronic measures to promote lung health'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Palliative care
         </strong>
         – The high symptom burden caused by advanced CF lung disease should be addressed by early inclusion of palliative care approaches by the patient's management team [
         <a href="#rid13">
          13,14
         </a>
         ]. Introduction of palliative care does not preclude continuing aggressive pulmonary care, including intensive care unit (ICU) admission, mechanical ventilation in the event of respiratory failure, or movement toward lung transplantation. A randomized study is underway to determine the effect of providing longitudinal palliative care delivered by a palliative care expert [
         <a href="#rid15">
          15
         </a>
         ]. Consensus guidelines from the CF Foundation encourage providing palliative care services to patients with CF and provide models for their implementation [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">
          "Benefits, services, and models of subspecialty palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6252.html" rel="external">
          "Pediatric palliative care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial support
         </strong>
         – Deteriorating pulmonary status generates increasing levels of depression and anxiety, and these may be exacerbated by financial challenges due to threats to employment and medical costs [
         <a href="#rid16">
          16
         </a>
         ]. When the severity of a patient's pulmonary disease becomes advanced, mental health should be assessed more frequently using tools such as PHQ-9 and GAD-7 and by interview during clinic visits. Mental health counseling should be offered early in the course of disease, with addition of psychotherapeutic medications if needed. The CF care team should assess the patient's financial status regularly, including access to adequate food, with referrals to support programs when needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H438574516">
         <span class="h1">
          LUNG TRANSPLANT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advancements in the treatment of CF lung disease have slowed the rate of disease progression, but premature death from respiratory failure still occurs in the majority of patients. As in other progressive lung diseases, lung transplantation provides a management option [
         <a href="#rid17">
          17
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">
          "Lung transplantation: An overview"
         </a>
         ). Of note, the frequency of lung transplantation for CF declined precipitously with the introduction of the highly effective CF transmembrane conductance regulator (CFTR) modulator combination
         <a class="drug drug_pediatric" data-topicid="122969" href="/z/d/drug information/122969.html" rel="external">
          elexacaftor-tezacaftor-ivacaftor
         </a>
         [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators", section on 'Pulmonary outcomes'
         </a>
         .)
        </p>
        <p>
         Virtually all lung transplants for patients with CF require replacing both lungs because leaving a native lung in place would present a huge source of infected secretions that would threaten the transplanted lung. A registry compiled by the International Society for Heart and Lung Transplantation (ISHLT) reports that 1220 lung transplants were performed in children with CF from January 1992 through June 2017 [
         <a href="#rid20">
          20
         </a>
         ] and 9428 lung transplants were performed in adults with CF from January 1992 to June 2017 [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4108136639">
         <span class="h2">
          Indications for referral to a lung transplant center
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2019, a consensus committee of the CF Foundation published guidelines that emphasize beginning the process of lung transplant referral well before a patient with advanced lung disease reaches end-stage [
         <a href="#rid22">
          22
         </a>
         ]. Of note, these guidelines were written prior to the widespread use of highly effective CFTR modulator therapy that rapidly improves lung function and slows its subsequent progression (see
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         ). However, the recommendation for early referral to a transplant center remains valid because a transplant center may be able to identify and address modifiable factors that could delay or prevent future transplant listing or adversely affect outcome.
        </p>
        <p>
         The guidelines recommend that the CF care team engage the patient and family in routine periodic discussion of the disease trajectory and treatment options including lung transplantation as a therapeutic option when the patient's forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) falls to &lt;50 percent predicted. Meanwhile, modifiable barriers to lung transplantation should be addressed to optimize candidacy, including nutritional status, optimal management of CF-related diabetes, physical deconditioning, adherence to the medical regimen, and any psychosocial or mental health challenges. Prophylactic sinus surgery in the pretransplant period has not been shown to improve transplant outcomes and is not recommended by guidelines unless done to relieve symptoms unresponsive to medical therapy [
         <a href="#rid9">
          9,10,23
         </a>
         ].
        </p>
        <p>
         The CF Foundation has defined a series of indications for referral to a lung transplant center, as listed in the table  (
         <a class="graphic graphic_table graphicRef121061" href="/z/d/graphic/121061.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. Key indications for referral are a FEV
         <sub>
          1
         </sub>
         &lt;50 percent predicted for those with a rapidly declining FEV
         <sub>
          1
         </sub>
         (&gt;20 percent relative decline in the previous year), FEV
         <sub>
          1
         </sub>
         &lt;40 percent predicted with markers of shortened survival, and FEV
         <sub>
          1
         </sub>
         &lt;30 percent predicted for all others. Adolescent patients are generally referred at higher FEV
         <sub>
          1
         </sub>
         values than adults because reaching advanced lung disease at an early age implies more aggressive lung disease with shortened survival compared with adults with the same FEV
         <sub>
          1
         </sub>
         percent predicted.
        </p>
        <p>
         Patients with FEV
         <sub>
          1
         </sub>
         &lt;40 percent predicted should undergo an annual six-minute walk test, assessment of need for supplemental oxygen, and venous blood gas to screen for markers of severe lung disease that may warrant transplant referral. To screen for pulmonary hypertension, a baseline echocardiogram should be performed for adult patients with FEV
         <sub>
          1
         </sub>
         &lt;40 percent predicted or for younger patients with FEV
         <sub>
          1
         </sub>
         &lt;50 percent predicted.
        </p>
        <p>
         Patients in North America should be referred to a transplant center that is also an accredited
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cff.org%2Fmanaging-cf%2Fcare-centers&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLBTz%2FUY37%2BD1jCXNFNZR%2FcukWdWwqnyRMoiDI5uIE7KRLXZEwbUjF6PzYmt4%2BAT3gg%3D%3D&amp;TOPIC_ID=129117" target="_blank">
          Cystic Fibrosis Foundation Care Center
         </a>
         [CFFCC], if possible. These centers provide specialized management for problems associated with CF such as malnutrition, sinus disease, bone disease, CF-related diabetes, and less common infections. In a study of more than 2500 patients, those who underwent transplant at a hospital with a CFFCC had a 33 percent reduction in risk of death or re-transplantation compared with those undergoing transplantation at a hospital without a CFFCC [
         <a href="#rid24">
          24
         </a>
         ]. Most (50 of 68) of the lung transplant centers involved in this study did have an affiliated CFFCC. To guide post-transplant management, the CF Foundation has published a consensus statement containing 32 recommendations covering a broad range of post-transplant topics [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Pediatric patients with CF require a somewhat more individualized approach [
         <a href="#rid25">
          25
         </a>
         ]. Importantly, there are few pediatric lung transplant centers, so distance and relocation burdens for families of children and adolescents with CF may be more imposing. Furthermore, there is evidence that outcomes after referral of children and adolescents to adult lung transplant programs have been suboptimal [
         <a href="#rid26">
          26
         </a>
         ]. The reasons are multiple but include the drop in adherence to medication that has been described in adolescents receiving solid organ transplants [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2028216014">
         <span class="h2">
          Lung allocation and wait list
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since March 2023, in the United States, the position of each lung transplant candidate on the priority list for transplant is determined by a lung composite allocation score (CAS) formulated by the United Network for Organ Sharing (UNOS). The CAS is calculated using estimates of one-year survival without transplant and five-year survival with transplant. It also compensates for delays due to difficulty with identifying a suitable donor, the historically low access to transplant of those less than age 18 years, and logistical issues regarding transferring the donor lung to the recipient site. Details about the scoring system and an approximate
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fdata%2Fallocation-calculators%2Flung-cas-calculator%2F&amp;token=8CWIkpM2hckDb9NZ0y5EDWzsqUo6KO%2BgV2TMBlkj%2FNBmPpE9hyQ04W5A9qLw6gcKqbw%2BP%2BY0EGXbuO9xT%2FfmWjIR5bb8OYh2NhZC8FcxZhw%3D&amp;TOPIC_ID=129117" target="_blank">
          lung CAS calculator
         </a>
         are available from the Organ Procurement and Transplantation Network [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         There are wide variations in the length of waiting lists among transplant centers, and individual patients may be served by exploring a number of different lung transplant centers. Noninvasive positive-pressure ventilation (NIPPV), endotracheal intubation, and extracorporeal membrane oxygenation (ECMO) have been used to bridge patients to transplantation [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Respiratory support'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2846430349">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Each transplant center has its own list of relative and absolute contraindications for lung transplantation. Because some of these contradictions are relatively subjective, a patient who is denied listing at one transplant center should be considered for referral to another. Some of the criteria that are more subjective and open to interpretation include those involving psychosocial situations, nonadherence to medical treatment, and substance use disorders [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         In addition to the general contraindications for lung transplantation applicable for all disease indications, there are several CF-specific considerations. Chronic infection with
         <em>
          Burkholderia cenocepacia
         </em>
         connotes a worse prognosis following transplantation [
         <a href="#rid30">
          30-34
         </a>
         ]. Most, but not all, transplant centers consider infection with this organism to be a contraindication to the procedure [
         <a href="#rid29">
          29,34
         </a>
         ]. Other species of
         <em>
          Burkholderia
         </em>
         do not appear to have the same adverse effects, with the possible exception of
         <em>
          Burkholderia gladioli
         </em>
         [
         <a href="#rid30">
          30-33
         </a>
         ]. Patients infected with multidrug-resistant
         <em>
          P. aeruginosa
         </em>
         have a minor, if any, survival disadvantage following lung transplant [
         <a href="#rid35">
          35,36
         </a>
         ]. Those infected with
         <em>
          Mycobacterium abscessus
         </em>
         frequently develop post-transplant complications and should be evaluated by centers with experience managing this infection [
         <a href="#rid37">
          37
         </a>
         ]. Similarly, there is increased risk of dissemination of the fungi
         <em>
          Scedosporium
         </em>
         <em>
          apiospermum
         </em>
         and
         <em>
          Lomentospora
         </em>
         <em>
          prolificans
         </em>
         post-transplant and patients with these infections should be assessed at transplant centers experienced with their management [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Respiratory colonization with
         <em>
          Aspergillus
         </em>
         is not a contraindication for transplantation but is associated with a substantially increased risk for post-transplant invasive aspergillosis [
         <a href="#rid38">
          38
         </a>
         ]. As a result, many centers employ antifungal prophylaxis after lung transplantation. (See
         <a class="local">
          'Outcomes'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">
          "Lung transplantation: Disease-based choice of procedure"
         </a>
         .)
        </p>
        <p>
         Most lung transplant centers in the United States will not accept the referral of intubated patients in acute respiratory failure for lung transplant evaluation. The survival of these patients without transplantation is poor, and prolonged intensive care unit (ICU) stays are associated with progressive deconditioning of affected individuals, another strong contraindication to transplantation in many centers. In addition, their poor clinical status prohibits education and informed consent of the patient, who is expected to adhere to a post-transplant regimen that is complex and can be onerous.
        </p>
        <p>
         Symptomatic osteoporosis is a relative contraindication for lung transplantation in general, but it takes on special significance for patients with CF. The frequency of osteopenia, osteoporosis, or bone fractures in CF increases with age and affects approximately 20 percent of individuals at age 25 years, increasing to 40 percent at age 55 years [
         <a href="#rid39">
          39
         </a>
         ]. Thus, presymptomatic diagnosis and treatment of osteopenia/osteoporosis is important to avoid exclusion of a patient from consideration for transplantation.
        </p>
        <p>
         A consensus document from the ISHLT addressing transplantation for all causes reported that a body mass index (BMI) &lt;17 kg/m
         <sup>
          2
         </sup>
         is a risk factor for an unfavorable outcome [
         <a href="#rid29">
          29
         </a>
         ]. This was confirmed in a CF population in a retrospective study of 2195 transplant recipients, in which the median survival was lower for those with a BMI &lt;17 kg/m
         <sup>
          2
         </sup>
         compared with those with BMI above this threshold
         <sup>
         </sup>
         (7.0 versus 8.2 years, respectively) [
         <a href="#rid40">
          40
         </a>
         ]. However, it was noted that the low-BMI cohort still had favorable outcomes compared with all patients transplanted for chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis. Therefore, a low BMI alone should not be considered a contraindication for referral to a transplant center [
         <a href="#rid41">
          41
         </a>
         ]. The ISHLT consensus document also noted that a BMI &gt;35 kg/m
         <sup>
          2
         </sup>
         is correlated with worse outcome [
         <a href="#rid29">
          29
         </a>
         ]. This observation is becoming more pertinent to CF as the prevalence of obesity in people with CF will likely increase with the use of highly effective CFTR modulators (see
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         ). For children, nutrition status is monitored by BMI Z-scores (or percentiles) because normal values for BMI vary during childhood. (See
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues", section on 'Growth'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3236958590">
         <span class="h2">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among adult patients with CF who underwent lung transplantation between 1992 and 2017, the median (50 percent) survival was 9.9 years [
         <a href="#rid21">
          21
         </a>
         ], which is significantly better than the survival for patients who are transplanted for other disease indications  (
         <a class="graphic graphic_figure graphicRef65977" href="/z/d/graphic/65977.html" rel="external">
          figure 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">
          "Lung transplantation: An overview"
         </a>
         ). Reports of survival data from single centers restricting the analysis to more recent experience suggest that survival may be improving [
         <a href="#rid34">
          34,42,43
         </a>
         ]. Analysis using UNOS registry data of the 13,040 patients listed for lung transplant between 2005 and 2011 found a clear survival advantage for the 70 percent who underwent transplantation [
         <a href="#rid44">
          44
         </a>
         ]. Using the same registry, a study reported that median survival of those age &gt;30 years was better than those age 18 to 29 years (9.5 and 5.2 years, respectively) [
         <a href="#rid45">
          45
         </a>
         ]. Post-transplant outcomes for CF lung transplant in Canada are better than in the United States, with part of the difference due to more United States patients dying while on the waiting list and better post-transplant survival in Canada [
         <a href="#rid46">
          46
         </a>
         ]. Pediatric patients receiving lung transplants for CF between 1992 and 2017 had a 50 percent survival of 5.6 years, which is similar to the 5.4-year median survival for pediatric patients who were transplanted for other indications [
         <a href="#rid20">
          20
         </a>
         ]. Data from two single-center reports provide a mixed picture of how much of the decreased pediatric survival was attributable to children under age 12 years; adolescents had survival rates similar to adults [
         <a href="#rid34">
          34,47
         </a>
         ]. Outcomes following re-transplantation are significantly worse, with a five-year median survival of 48 percent compared with 59 percent for those undergoing their first transplant [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1862001445">
         <span class="h2">
          Limitations of transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many problems remain after lung transplantation for CF. The procedure does not address the nonpulmonary problems associated with CF. Chronic sinusitis, cirrhosis, cholelithiasis, pancreatic insufficiency, CF-associated diabetes mellitus, osteoporosis, and distal intestinal obstruction syndrome remain causes of morbidity and occasionally of mortality. Pancreatic insufficiency and abnormalities in bowel motility can make
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         absorption and dosing difficult;
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         itself is diabetogenic. Glucocorticoid treatment to suppress graft rejection complicates diabetic management and accelerates osteoporosis. Studies examining quality of life after lung transplantation for CF generally show improvement [
         <a href="#rid49">
          49-51
         </a>
         ]. Most children return to school, and many adults return to work.
        </p>
        <p class="headingAnchor" id="H2659637078">
         <span class="h1">
          RESPIRATORY SUPPORT
         </span>
        </p>
        <p class="headingAnchor" id="H879667400">
         <span class="h2">
          Supplemental oxygen
         </span>
         <span class="headingEndMark">
          —
         </span>
         For CF patients with intermittent or chronic hypoxemia, we suggest supplemental oxygen, consistent with guidelines from the CF Foundation and American Thoracic Society [
         <a href="#rid1">
          1,52
         </a>
         ]. This approach is extrapolated from the management of patients with chronic obstructive pulmonary disease (COPD), in whom supplemental oxygen delays or ameliorates the complications of chronic hypoxemia [
         <a href="#rid53">
          53
         </a>
         ]. In the absence of studies examining oxygen use in patients with CF, we follow the same recommendations for use as in patients with COPD. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1448.html" rel="external">
          "Evaluation of patients for supplemental oxygen during air travel"
         </a>
         .)
        </p>
        <p>
         Short-term outcomes of supplemental oxygen therapy during exercise and sleep were evaluated in a systematic review of 10 small randomized controlled trials of patients with CF [
         <a href="#rid54">
          54
         </a>
         ]. Supplemental oxygen modestly enhanced exercise duration and capacity, improved attendance at school or work, and caused mild hypercapnia that is probably clinically insignificant. Use of nocturnal oxygen improved time to fall asleep but did not improve qualitative sleep parameters. Only one of the studies in the systematic review examined long-term oxygen therapy [
         <a href="#rid55">
          55
         </a>
         ]. No statistically significant improvement in survival, lung function, or cardiac health was detected. In addition, improvement of oxygenation was accompanied by modest hypercapnia that was probably clinically inconsequential.
        </p>
        <p class="headingAnchor" id="H2406400379">
         <span class="h2">
          Nocturnal noninvasive positive-pressure ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally offer nocturnal noninvasive bilevel positive airway pressure (BPAP) ventilation to patients whose arterial carbon dioxide level remains elevated (eg, ≥55 mmHg, or ≥50 mmHg with nocturnal desaturation) despite maximizing other treatments. (See
         <a class="medical medical_review" href="/z/d/html/1453.html" rel="external">
          "Nocturnal ventilatory support in COPD"
         </a>
         .)
        </p>
        <p>
         This approach is supported by a systematic review in which noninvasive positive-pressure ventilation (NIPPV) for patients with advanced CF lung disease and hypercapnia improved gas exchange during sleep [
         <a href="#rid56">
          56
         </a>
         ]. One of the included trials involved eight adults with daytime hypercapnia and compared nocturnal use of BPAP to supplemental oxygen or placebo (air) [
         <a href="#rid57">
          57
         </a>
         ]. Six weeks of BPAP improved self-reported chest symptoms, exertional dyspnea and exercise capacity, nocturnal hypoventilation, and peak exercise capacity, without measurable improvement in lung function, and was tolerated by 90 percent of patients. In another study, 29 patients with nocturnal oxygen desaturations who were randomized to noninvasive ventilation had improved event-free survival at 3 and 12 months compared to those receiving supplemental oxygen alone. Events were defined as an arterial partial pressure of carbon dioxide (PaCO
         <sub>
          2
         </sub>
         ) &gt;60 mmHg or a partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ) increase of &gt;10 mmHg measured by arterial blood gas or by transcutaneous CO
         <sub>
          2
         </sub>
         monitor [
         <a href="#rid58">
          58
         </a>
         ]. Several case series also reported successful long-term use of NIPPV as a bridge to transplant; the intervention was associated with improved hypercarbia, weight gain, and/or improvement in the trajectory for forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) [
         <a href="#rid59">
          59-62
         </a>
         ]. A small crossover trial in adults with advanced CF lung disease reported that NIPPV and high-flow oxygen therapy resulted in similar oxygenation and work of breathing [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1565145570">
         <span class="h2">
          Intensive care unit treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis following an episode of mechanical ventilation due to acute respiratory failure in advanced CF lung disease has been improving, with 36 to 56 percent surviving until hospital discharge [
         <a href="#rid1">
          1,64,65
         </a>
         ]. Outcomes for children and adolescents who are admitted to intensive care may be somewhat better than for adults. In a large study from a registry of pediatric intensive care units (ICUs; primarily in North America), mortality during the ICU admission was 6.9 percent overall and 19.1 percent for patients who were intubated [
         <a href="#rid66">
          66
         </a>
         ]. However, it is unclear what proportion of this cohort was admitted to the ICU with respiratory failure. Thus, advanced CF lung disease is not a contraindication to ICU care and mechanical ventilation, regardless of the patient's lung transplant status [
         <a href="#rid1">
          1
         </a>
         ]. Interventions may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noninvasive respiratory support
         </strong>
         – Heated high-flow oxygen or NIPPV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endotracheal intubation
         </strong>
         – Endotracheal intubation with mechanical ventilation is not contraindicated in advanced CF lung disease. It is particularly beneficial when the acute decompensation is caused by pneumothorax or hemoptysis but should be considered for all causes of respiratory failure. If endotracheal intubation is required for more than five to seven days, early tracheostomy should be considered to promote physical mobilization to avoid deconditioning and reduce the need for sedation [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations", section on 'Respiratory support'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extracorporeal membrane oxygenation support (ECMO)
         </strong>
         – Venovenous ECMO is sometimes employed as a bridge to lung transplant in CF patients who are approved for transplantation [
         <a href="#rid1">
          1,67,68
         </a>
         ]. In addition, in highly selected patients, ECMO may be considered as a bridge to recovery, based on anecdotal reports as outlined in the CF Foundation guideline [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Decisions about ICU admission and each of the above interventions must be individualized, depending on the patient's prognosis for recovery or lung transplantation and on their desires and preferences, as expressed in advanced care directives. (See
         <a class="local">
          'Advanced care directives'
         </a>
         above.)
        </p>
        <p>
         In the past, outcomes for CF patients requiring treatment in an ICU were uniformly poor [
         <a href="#rid69">
          69
         </a>
         ] but have since fortunately improved [
         <a href="#rid70">
          70
         </a>
         ]. There are probably multiple reasons for the improved outcomes, including the use of noninvasive ventilation to sustain the patient until other measures to reverse the respiratory failure take effect [
         <a href="#rid71">
          71,72
         </a>
         ]. In modern series, survival was dependent upon the severity of respiratory failure, with the best outcomes for those who could be managed by noninvasive ventilation and the worst for those requiring endotracheal intubation/ventilation [
         <a href="#rid64">
          64,65,72-75
         </a>
         ]. Patients requiring ICU treatment admission for pneumothorax or hemoptysis had a better prognosis as compared with CF patients admitted to the ICU for other indications [
         <a href="#rid75">
          75,76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Spontaneous pneumothorax'
         </a>
         and
         <a class="local">
          'Hemoptysis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H320237814">
         <span class="h2">
          Hemoptysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood streaking in sputum is a common occurrence in patients with CF and is often accompanied by other signs of a pulmonary exacerbation. (See
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
         Massive hemoptysis is defined in the CF population as acute bleeding of more than 240 mL within 24 hours or recurrent bleeding of more than 100 mL daily for several days [
         <a href="#rid77">
          77
         </a>
         ]. It is more common in patients with advanced lung disease (approximately 2 percent of these patients per year), but can also occur in other patients who have regions of the lung with advanced bronchiectasis [
         <a href="#rid78">
          78-80
         </a>
         ]. Massive hemoptysis increases the risk of progression to lung transplant and death without lung transplant [
         <a href="#rid22">
          22,78
         </a>
         ]. In patients with severe lung disease, massive hemoptysis is an indication for lung transplant referral [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Evaluation and management of hemoptysis in people with CF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Hemoptysis'
         </a>
         .)
        </p>
        <p>
         Emergency management of unstable patients with massive hemoptysis (hemodynamic instability or impending respiratory failure) is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6370.html" rel="external">
          "Hemoptysis in children", section on 'Control of life-threatening hemoptysis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3420272038">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109226.html" rel="external">
          "Society guideline links: Cystic fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1867631263">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16906.html" rel="external">
          "Patient education: Cystic fibrosis (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86714.html" rel="external">
          "Patient education: Bronchiectasis in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2649081409">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Cystic fibrosis (CF)-related lung disease is considered advanced if the forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) is &lt;40 percent predicted or the patient is referred for lung transplantation evaluation, or if the patient has one of several clinical characteristics that are associated with worse pulmonary status, such as chronic hypercarbia. (See
         <a class="local">
          'Definition of advanced cystic fibrosis lung disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Key interventions for all patients
         </strong>
         – When CF-related lung disease progresses to an advanced stage, special attention should be given to optimizing key therapies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CF transmembrane conductance regulator (CFTR) modulators
         </strong>
         – Therapy with a CFTR modulator therapy is recommended for most patients with advanced lung disease, as for other patients with CF. Recommendations for CFTR therapy are summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130532" href="/z/d/graphic/130532.html" rel="external">
          algorithm 1
         </a>
         ) and discussed separately. (See
         <a class="local">
          'Key therapies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators", section on 'Patients with advanced lung disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other key therapies
         </strong>
         – Other key therapies that should be optimized for this group of patients are pulmonary rehabilitation, nutritional support, screening and management of CF-related diabetes, and continuous alternating inhaled antibiotics (for those with
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         infection). (See
         <a class="local">
          'Key therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Psychosocial support
         </strong>
         – The patient's care program should place increased emphasis on maintaining mental health. Levels of anxiety and depression should be measured and treated with counseling and medication, when needed. Discussion of advanced care directives and palliative care strategies should be introduced early and do not preclude aggressive pulmonary care and consideration for lung transplantation. (See
         <a class="local">
          'Advanced care directives'
         </a>
         above and
         <a class="local">
          'Psychosocial support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional interventions for selected patients
         </strong>
         – Decisions about advanced care must be individualized, depending on the patient's desires and preferences as expressed in advanced care directives, as well as their prognosis for recovery or lung transplantation. Strategies may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lung transplantation
         </strong>
         – Severe CF lung disease is a common indication for lung transplantation, and outcomes are better than those of patients undergoing lung transplantation for other indications. Guidelines emphasize beginning the process of lung transplant referral well before a patient with advanced lung disease reaches end-stage and suggest clinical indications for referral, as outlined in the table  (
         <a class="graphic graphic_table graphicRef121061" href="/z/d/graphic/121061.html" rel="external">
          table 1
         </a>
         ). Chronic infection with
         <em>
          Burkholderia cenocepacia
         </em>
         connotes a worse prognosis following transplantation and is often considered a contraindication to the procedure. (See
         <a class="local">
          'Lung transplant evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Palliative care
         </strong>
         – As symptom burden increases and quality of life deteriorates, palliative care strategies should be introduced without precluding continuation of other therapies or eligibility for lung transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Supplemental oxygen
         </strong>
         – For patients with chronic hypoxemia due to advanced CF lung disease, we suggest supplemental oxygen therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), using the same indications as for patients with chronic obstructive pulmonary disease (COPD). Supplemental oxygen may improve exercise capacity and attendance at school or work and causes mild hypercapnia that is probably clinically insignificant. The possibility of long-term benefits is extrapolated from studies in patients with COPD and has not been demonstrated in patients with CF. (See
         <a class="local">
          'Supplemental oxygen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nocturnal noninvasive positive-pressure ventilation (NIPPV)
         </strong>
         – For patients with persistent hypercarbia (arterial carbon dioxide level ≥55 mmHg, or ≥50 mmHg with nocturnal desaturation) despite maximizing other treatments, we suggest nocturnal NIPPV (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). NIPPV is tolerated by most patients and improves self-reported chest symptoms, exertional dyspnea and exercise capacity, nocturnal hypoventilation, and peak exercise capacity. (See
         <a class="local">
          'Nocturnal noninvasive positive-pressure ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intensive care
         </strong>
         – Improved outcomes support use of intensive care unit (ICU) care for CF patients with respiratory failure. Interventions may include heated high-flow oxygen and NIPPV. Similarly, having advanced CF should not preclude endotracheal intubation with mechanical ventilation, tracheostomy, and extracorporeal membrane oxygenation (ECMO) for select patients. (See
         <a class="local">
          'Intensive care unit treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros 2020; 19:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shteinberg M, Taylor-Cousar JL. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev 2020; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgel PR, Durieu I, Chiron R, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med 2021; 204:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos KJ, Guimbellot JS, Valapour M, et al. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients. J Cyst Fibros 2022; 21:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes D Jr, Darland LK, Hjelm MA, et al. To treat or not to treat: CFTR modulators after lung transplantation. Pediatr Transplant 2021; 25:e14007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzenberg SJ, Hempstead SE, McDonald CM, et al. Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. J Cyst Fibros 2016; 15:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakir S, Echevarria C, Doe S, et al. Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros 2022; 21:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin M, Gao X, Di L, et al. Effect of Endoscope Sinus Surgery on Pulmonary Function in Cystic Fibrosis Patients: A Meta-Analysis. Laryngoscope 2021; 131:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimple AJ, Senior BA, Naureckas ET, et al. Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol 2022; 12:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spielman DB, Beswick DM, Kimple AJ, et al. The management of cystic fibrosis chronic rhinosinusitis: An evidenced-based review with recommendations. Int Forum Allergy Rhinol 2022; 12:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flume PA, Clancy JP, Retsch-Bogart GZ, et al. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros 2016; 15:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishay LC, Sawicki GS. Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther 2016; 7:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman D, Linnemann RW, Altstein LL, et al. Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis. Pediatr Pulmonol 2019; 54:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavalieratos D, Georgiopoulos AM, Dhingra L, et al. Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines. J Palliat Med 2021; 24:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowers J, Dellon EP, Stephenson A, et al. Integrating specialist palliative care to improve care and reduce suffering: cystic fibrosis (InSPIRe:CF) - study protocol for a multicentre randomised clinical trial. BMJ Open Respir Res 2022; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quittner AL, Abbott J, Georgiopoulos AM, et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax 2016; 71:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilewski JM. Update on Lung Transplantation for Cystic Fibrosis. Clin Chest Med 2022; 43:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin C, Reynaud-Gaubert M, Hamidfar R, et al. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. J Cyst Fibros 2022; 21:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avdimiretz N, Benden C. The changing landscape of pediatric lung transplantation. Clin Transplant 2022; 36:e14634.
          </a>
         </li>
         <li class="breakAll">
          International Society for Heart and Lung Transplantation. Lung Transplantation: Pediatric Recipients slides. 2019. Available at: https://ishltregistries.org/downloadables/slides/2019/lung_pediatric.pptx (Accessed on July 06, 2022).
         </li>
         <li class="breakAll">
          International Society for Heart and Lung Transplantation. Lung Transplantation: Adult Recipients slides. 2019. Available at: https://ishltregistries.org/downloadables/slides/2019/lung_adult.pptx (Accessed on July 06, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah P, Lowery E, Chaparro C, et al. Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients. J Heart Lung Transplant 2021; 40:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush EL, Krishnan A, Chidi AP, et al. The effect of the cystic fibrosis care center on outcomes after lung transplantation for cystic fibrosis. J Heart Lung Transplant 2022; 41:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon M, Mallory GB. Lung transplant referrals for individuals with cystic fibrosis: A pediatric perspective on the cystic fibrosis foundation consensus guidelines. Pediatr Pulmonol 2021; 56:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scully BB, Goss M, Liu H, et al. Waiting list outcomes in pediatric lung transplantation: Poor results for children listed in adult transplant programs. J Heart Lung Transplant 2017; 36:1201.
          </a>
         </li>
         <li class="breakAll">
          Organ Procurement &amp; Transplantation Network. Heart &amp; lung. Available at: https://optn.transplant.hrsa.gov/resources/by-organ/heart-lung/ (Accessed on May 10, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schechter MA, Ganapathi AM, Englum BR, et al. Spontaneously Breathing Extracorporeal Membrane Oxygenation Support Provides the Optimal Bridge to Lung Transplantation. Transplantation 2016; 100:2699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeung JC, Machuca TN, Chaparro C, et al. Lung transplantation for cystic fibrosis. J Heart Lung Transplant 2020; 39:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lay C, Law N, Holm AM, et al. Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: An ISHLT Registry‒based analysis. J Heart Lung Transplant 2019; 38:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobo LJ, Chang LC, Esther CR Jr, et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013; 27:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014; 97:351.
          </a>
         </li>
         <li class="breakAll">
          Cystic Fibrosis Foundation. 2021 Patient Registry: Annual Data Report. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf (Accessed on November 10, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos KJ, Kapnadak SG, Bradford MC, et al. Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation: A United Network for Organ Sharing Registry Study. Chest 2020; 157:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennerich AL, Pryor JB, Wai TYH, et al. Low body mass index as a barrier to lung transplant in cystic fibrosis. J Cyst Fibros 2022; 21:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vos R, Verleden GM, Dupont LJ. Long-term survival after lung transplantation among cystic fibrosis patients: Moving away from mere palliation. J Heart Lung Transplant 2016; 35:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephenson AL, Sykes J, Berthiaume Y, et al. Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. J Heart Lung Transplant 2015; 34:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vock DM, Durheim MT, Tsuang WM, et al. Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation. Ann Am Thorac Soc 2017; 14:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi J, Bugajski A, Patel KN, et al. Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation. Ann Am Thorac Soc 2021; 18:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephenson AL, Ramos KJ, Sykes J, et al. Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States. J Heart Lung Transplant 2021; 40:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melicoff E, Ruiz FE, Hosek K, Mallory GB. Cystic fibrosis lung transplant recipients 10 years of age or younger: Predisposing factors for end-stage disease. Pediatr Pulmonol 2022; 57:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan EG, Hyzny EJ, Ryan JP, et al. Outcomes following lung re-transplantation in patients with cystic fibrosis. J Cyst Fibros 2022; 21:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeritschnig B, Jaksch P, Kocher A, et al. Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant 2005; 24:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kugler C, Fischer S, Gottlieb J, et al. Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant 2005; 24:2262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nixon PA, Morris KA. Quality of life in pediatric heart, heart-lung, and lung transplant recipients. Int J Sports Med 2000; 21 Suppl 2:S109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes D Jr, Wilson KC, Krivchenia K, et al. Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 199:e5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125:1S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; :CD003884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zinman R, Corey M, Coates AL, et al. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Pediatr 1989; 114:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2017; 2:CD002769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AC, Wilson JW, Kotsimbos TC, Naughton MT. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milross MA, Piper AJ, Dwyer TJ, et al. Non-invasive ventilation versus oxygen therapy in cystic fibrosis: A 12-month randomized trial. Respirology 2019; 24:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AT, Edenborough FP, Cayton RM, Stableforth DE. Long-term nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991-1996). Respir Med 1998; 92:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efrati O, Modan-Moses D, Barak A, et al. Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation. Isr Med Assoc J 2004; 6:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flight WG, Shaw J, Johnson S, et al. Long-term non-invasive ventilation in cystic fibrosis -- experience over two decades. J Cyst Fibros 2012; 11:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadsworth LE, Belcher J, Bright-Thomas RJ. Non-invasive ventilation is associated with long-term improvements in lung function and gas exchange in cystic fibrosis adults with hypercapnic respiratory failure. J Cyst Fibros 2021; 20:e40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sklar MC, Dres M, Rittayamai N, et al. High-flow nasal oxygen versus noninvasive ventilation in adult patients with cystic fibrosis: a randomized crossover physiological study. Ann Intensive Care 2018; 8:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siuba M, Attaway A, Zein J, et al. Mortality in Adults with Cystic Fibrosis Requiring Mechanical Ventilation. Cross-Sectional Analysis of Nationwide Events. Ann Am Thorac Soc 2019; 16:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oud L. Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes. PLoS One 2017; 12:e0186770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MA, McGarry ME, Ly NP, Zinter MS. Outcomes of Children With Cystic Fibrosis Admitted to PICUs. Pediatr Crit Care Med 2020; 21:e879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schellongowski P, Riss K, Staudinger T, et al. Extracorporeal CO2 removal as bridge to lung transplantation in life-threatening hypercapnia. Transpl Int 2015; 28:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson K, Staffa SJ, Nasr VG, et al. Mortality after Lung Transplantation for Children Bridged with Extracorporeal Membrane Oxygenation. Ann Am Thorac Soc 2022; 19:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis PB, di Sant'Agnese PA. Assisted ventilation for patients with cystic fibrosis. JAMA 1978; 239:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibilaro JM, Keating C, Benvenuto L, et al. Survival in cystic fibrosis after acute respiratory failure supported by extracorporeal membrane oxygenation and/or invasive mechanical ventilation. J Cyst Fibros 2022; 21:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madden BP, Kariyawasam H, Siddiqi AJ, et al. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. Eur Respir J 2002; 19:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Texereau J, Jamal D, Choukroun G, et al. Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respir Res 2006; 7:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellaffi M, Vinsonneau C, Coste J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 171:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efrati O, Bylin I, Segal E, et al. Outcome of patients with cystic fibrosis admitted to the intensive care unit: is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation? Heart Lung 2010; 39:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slieker MG, van Gestel JP, Heijerman HG, et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006; 32:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones A, Bilton D, Evans TW, Finney SJ. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology 2013; 18:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayomy OF, Ramos KJ, Hee Wai T, et al. Hemoptysis and the Risk for Lung Transplant or Death without Transplant in Individuals with Cystic Fibrosis in the United States. Ann Am Thorac Soc 2022; 19:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mingora CM, Flume PA. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest 2021; 160:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129117 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32115388" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32198216" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33600738" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35474016" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33742748" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : To treat or not to treat: CFTR modulators after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27599607" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35718668" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32949423" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of Endoscope Sinus Surgery on Pulmonary Function in Cystic Fibrosis Patients: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35089650" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34933415" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The management of cystic fibrosis chronic rhinosinusitis: An evidenced-based review with recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27233377" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27799838" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30854795" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32936045" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36126995" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Integrating specialist palliative care to improve care and reduce suffering: cystic fibrosis (InSPIRe:CF) - study protocol for a multicentre randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26452630" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36344083" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Update on Lung Transplantation for Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35123901" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35244236" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The changing landscape of pediatric lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35244236" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The changing landscape of pediatric lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35244236" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The changing landscape of pediatric lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30926322" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34103223" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34930671" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The effect of the cystic fibrosis care center on outcomes after lung transplantation for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33300243" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lung transplant referrals for individuals with cystic fibrosis: A pediatric perspective on the cystic fibrosis foundation consensus guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28579113" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Waiting list outcomes in pediatric lung transplantation: Poor results for children listed in adult transplant programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28579113" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Waiting list outcomes in pediatric lung transplantation: Poor results for children listed in adult transplant programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26910331" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Spontaneously Breathing Extracorporeal Membrane Oxygenation Support Provides the Optimal Bridge to Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34419372" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18535253" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impact of burkholderia infection on lung transplantation in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18408050" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18318775" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20810293" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32147452" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lung transplantation for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17692788" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30733155" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: An ISHLT Registry‒based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23710571" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24305637" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24305637" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31958441" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation: A United Network for Organ Sharing Registry Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34922852" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Low body mass index as a barrier to lung transplant in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26948564" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Long-term survival after lung transplantation among cystic fibrosis patients: Moving away from mere palliation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26087666" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27779905" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32795188" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33386232" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35243829" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cystic fibrosis lung transplant recipients 10 years of age or younger: Predisposing factors for end-stage disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34949557" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Outcomes following lung re-transplantation in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15797751" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Quality of life after lung transplantation: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16364880" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Health-related quality of life in two hundred-eighty lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11142595" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Quality of life in pediatric heart, heart-lung, and lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30707039" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734689" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cystic fibrosis adult care: consensus conference report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23888484" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Oxygen therapy for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2921681" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28218802" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Non-invasive ventilation for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17675317" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31206975" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Non-invasive ventilation versus oxygen therapy in cystic fibrosis: A 12-month randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9692116" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Long-term nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991-1996).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15373309" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177738" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Long-term non-invasive ventilation in cystic fibrosis -- experience over two decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34140250" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Non-invasive ventilation is associated with long-term improvements in lung function and gas exchange in cystic fibrosis adults with hypercapnic respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30187270" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : High-flow nasal oxygen versus noninvasive ventilation in adult patients with cystic fibrosis: a randomized crossover physiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31026405" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Mortality in Adults with Cystic Fibrosis Requiring Mechanical Ventilation. Cross-Sectional Analysis of Nationwide Events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29065161" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32304511" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Outcomes of Children With Cystic Fibrosis Admitted to PICUs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25387861" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Extracorporeal CO2 removal as bridge to lung transplantation in life-threatening hypercapnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34619069" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mortality after Lung Transplantation for Children Bridged with Extracorporeal Membrane Oxygenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/642113" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Assisted ventilation for patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34479809" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Survival in cystic fibrosis after acute respiratory failure supported by extracorporeal membrane oxygenation and/or invasive mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11866011" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16438722" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15502116" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20207276" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Outcome of patients with cystic fibrosis admitted to the intensive care unit: is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16518642" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23323684" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20675678" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35759341" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hemoptysis and the Risk for Lung Transplant or Death without Transplant in Individuals with Cystic Fibrosis in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34147501" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16100161" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Massive hemoptysis in cystic fibrosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
